Form 4: Pfizer Director Joseph Echevarria Reports Acquisition of Phantom Stock Units

Pfizer director Joseph Echevarria acquired 1,743.309 phantom stock units representing deferred compensation.

Summary

• Director Joseph Echevarria acquired 1,743.309 phantom stock units of Pfizer on December 31, 2024.
• These units represent deferred director's compensation, including dividend equivalents.
• The units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.
• The price of the underlying common stock at the time of the transaction was $26.53 per share.

Sentiment

Score: 7

Explanation: The document is a routine filing related to director compensation, which is a neutral event. The sentiment is slightly positive as it indicates alignment of director interests with the company's long-term performance.

Industry Context

This is a routine filing related to director compensation and is common practice for publicly traded companies.

Comparison to Industry Standards

• Director compensation packages often include deferred stock units, which are common across large publicly traded companies like Pfizer.
• Companies such as Johnson & Johnson (JNJ) and Merck (MRK) also use similar compensation structures for their board members.
• The use of phantom stock units is a standard method to align director interests with long-term shareholder value.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns director interests with the long-term performance of the company.

Key Dates

Keywords

phantom stock units, director compensation, insider trading, Form 4, Pfizer, PFE, deferred compensation